Clinical Trial Vanguard Newsletter April 1, 2024
CONFERENCE COVERAGE
The clinical trial industry faces a critical juncture as the dust settles from the COVID-19 pandemic. During the height of the pandemic, decentralized clinical trials (DCTs) and the use of digital health technologies (DHT) emerged as beacons of innovation, enabling research to continue despite global lockdowns.
In a pivotal webcast hosted by Medable, a panel of distinguished experts, including Pamela Tenaerts (Chief Scientific Officer at Medable), Barbara E. Bierer (Professor of Medicine at Harvard Medical School), and technology virtuosos Jeff Nicol (VP, Global Privacy at Medable), and Carl Franzetti (VP, Technology Operations at Medable), explored the burgeoning realm of DCTs
February 12, 2024, marked a significant moment at the SCOPE Summit 2024 as Rob Goodwin, Sr. VP and Head of Clinical Development and Operations at Pfizer, captivated the audience with a heartfelt narrative underlining the cruciality of time in clinical trials.
The recent IQVIA Clinical Trial Site Payments Webcast shed light on the intricacies of financial management in clinical trials, a topic of increasing complexity and importance. With the expertise of Rajiv Prasad, the Director of Financial Forecasting, and Jim DiCesare, Senior Director of Study Operations at IQVIA, the webinar dissected the multifarious challenges that clinical trial sites face and the necessity for an innovative approach to financial forecasting and payments.
EXECUTIVE INTERVIEWS AND ARTICLES
In the fast-changing world of pharmaceutical drug development, new digital twin technologies are beginning to make a significant impact. These technologies use advanced simulations, modeling, artificial intelligence, and big data to transform drug development.
Recommended by LinkedIn
A groundbreaking proof-of-concept study conducted by Medable and the Duke BASE Lab unveiled electronic informed consent (eConsent) solutions in clinical trials by demonstrating participant preference for an innovative enhanced version brimming with interactive digital elements such as videos, collapsible summaries and interactive quizzes against a traditional text-only eConsent version.
In an unprecedented move within the life sciences industry, Veeva announced the successful migration of 25 clinical studies for a top 20 biopharmaceutical company to Veeva Vault EDC, marking a significant industry milestone. This transition included a large-scale study involving over 500 research sites and 7,000 patients, and migrating a total of more than 55 million data points and five million forms.
PhotoPharmics, in partnership with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center (URMC), has initiated a groundbreaking pivotal trial named the “Celeste Light for PD Trial.” This significant research effort aims to evaluate the efficacy of the Celeste® phototherapy device in improving both non-motor and motor functions and the quality of life in patients with Parkinson’s Disease (PD).
TriSalus Life Sciences® Inc., an oncology company specializing in novel delivery technologies combined with immunotherapy for liver and pancreatic tumors, showcased its groundbreaking technology through two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting..
Volastra Therapeutics, a clinical-stage biotechnology company at the forefront of developing cancer treatments targeting chromosomal instability (CIN), has announced strategic collaborations with Microsoft, Function Oncology, and Tailor Bio. These partnerships aim to enhance the potential of Volastra’s therapeutic pipeline by identifying predictive biomarkers across various tumor types. This initiative can potentially extend the application of Volastra’s KIF18A inhibitors well beyond cancers characterized by universally high levels of CIN.